New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
04:55 EDTXLRN, XLRN, XLRN, AGIO, AGIO, AGIO, ALKS, ALKS, ALKS, ALNY, ALNY, ALNY, ARIA, ARIA, ARIA, EPZM, EPZM, EPZM, IMGN, IMGN, IMGN, TSRO, TSRO, TSROLeerink to hold a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 14-16.
News For XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO From The Last 14 Days
Check below for free stories on XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 14, 2014
05:36 EDTXLRNAcceleron initiated with an Outperform at FBR Capital
Target $47.
August 13, 2014
08:34 EDTAGIOAgios announces AG-221 fast track designation from FDA
Subscribe for More Information
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
06:29 EDTALNYAlnylam called at top mid-cap pick for second half at Piper Jaffray
Piper Jaffray calls Alnylam a top mid-cap pick for the second half of 2014 and reiterates an Overweight rating on the name with a $101 price target. Piper thinks shares can rally into 2015 based on data read-outs and pipeline expansion.
August 12, 2014
17:12 EDTEPZMEpizyme reports MTD not reached in 3 dose cohorts from EPZ-6438 Phase 1 trial
Subscribe for More Information
15:56 EDTEPZMEpizyme rises 5.3% to $35.93
A late day move higher in shares of Epizyme came in concert with the posting of a presentation dated August 12, entitled "EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations," to the company's website. Reference Link
15:55 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
15:23 EDTEPZMNotable companies reporting before tomorrow's open
Subscribe for More Information
07:01 EDTXLRNAcceleron reports Q2 EPS (52c), consensus (45c)
Subscribe for More Information
August 11, 2014
06:54 EDTEPZMAmerican Society of Hematology to hold a meeting
Subscribe for More Information
August 7, 2014
16:02 EDTALNYAlnylam reports Q2 EPS (63c), consensus (56c)
Subscribe for More Information
15:33 EDTALNY Notable companies reporting after market close
Subscribe for More Information
15:31 EDTEPZMEpizyme management to meet with JMP Securities
Subscribe for More Information
15:31 EDTALNYNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
08:11 EDTALNYAlnylam receives orphan drug designations in EU for ALN-AT3
Subscribe for More Information
07:37 EDTAGIOAgios Pharmaceuticals reports Q2 EPS (54c), consensus (41c)
Subscribe for More Information
07:31 EDTALNYAlnylam to hold a roundtable webinar
Roundtable where Alnylam scientists and key clinical collaborators review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas will be held on August 7 at 9:30 am. Webcast Link
07:27 EDTIMGNUBS to hold a conference
Subscribe for More Information
August 6, 2014
07:38 EDTARIAARIAD sees cash used in operations in FY14 $165M-$175M
Subscribe for More Information
07:37 EDTARIAARIAD reports Q2 EPS (30c), consensus (29c)
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use